This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Texas Research Institutions Conducted Over 8,200 Clinical Trials Of Medicines Since 1999

Report highlights illustrate the importance of clinical trials for new medicines to treat chronic disease:

  • More than 110,000 new cancer cases will be diagnosed this year in the state and 37,000 Texans will die of the disease, according to the American Cancer Society. Biopharmaceutical companies and their local research collaborators, including the M.D. Anderson Cancer Center at the University of Texas and the Texas Tech University Health Science Center, are currently conducting more than 600 trials of new cancer medicines that are recruiting patients.
  • Nearly 10 percent of the state's adults have been diagnosed with diabetes, which, in 2007, killed 5,105 diabetics in the Lone Star State. Currently, 92 clinical trials for diabetes are recruiting patients in Texas.
  • More than 189,000 state patients died of heart disease in 2009 and 46,000 from fatal strokes. 49 heart disease and 15 stroke clinical trials are seeking Texas patients.
  • About 833,000 Texas adults live with serious mental illness and about 288,000 children have significant mental health conditions, according to the National Alliance on Mental Illness. 96 clinical trials of new mental illness medicines are seeking patient participants in the Lone Star State.
  • The state's asthma toll is more than one million adults and nearly 600,000 children. 29 clinical trials of new asthma treatments are active and recruiting patients at institutions, such as Alamo Clinical Research in Austin.

Through biotechnology, researchers are developing new ways to improve our ability to predict and even prevent disease, providing hope for future generations. Among the 914 clinical trials still recruiting patients in the state, there are trials of a genetically-modified vaccine to treat melanoma, a fusion protein to treat diabetic macular edema and a new antibody that targets lupus and various cancers.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,781.26 -17.23 -0.10%
S&P 500 2,085.59 -4.52 -0.22%
NASDAQ 5,122.7910 -4.7340 -0.09%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs